当前位置: Nature » 生物医学 » 正文

Nature Communications:心脏病,一个小分子可能会产生大差别

摘要 : 本期Nature Communications上发表的一项研究显示,被称为BGP-15的一个小分子在关于心脏衰竭的两个小鼠模型中能改善心脏功能。人们希望,该发现将会导致人类心脏病新疗法的开发成功。


本期Nature Communications上发表的一项研究显示,被称为BGP-15的一个小分子在关于心脏衰竭的两个小鼠模型中能改善心脏功能。人们希望,该发现将会导致人类心脏病新疗法的开发成功。

心房颤动(最常见的心率异常)和心脏衰竭发病率在增长,但当前的药物疗效有限。Julie McMullen及同事发现,在关于心脏衰竭和心房颤动的小鼠模型中,用BGP-15进行治疗能防止或减少不规则心跳的出现次数,显著改善心脏功能。BGP-15作为其他疾病的一种治疗药物已经进行了人体试验,结果表明其耐受性很好、安全性也很好。


原文标题:The small-molecule ​BGP-15 protects against heart failure and atrial fibrillation in mice

原文摘要:Heart failure (HF) and atrial fibrillation (AF) share common risk factors, frequently coexist and are associated with high mortality. Treatment of HF with AF represents a major unmet need. Here we show that a small molecule, ​BGP-15, improves cardiac function and reduces arrhythmic episodes in two independent mouse models, which progressively develop HF and AF. In these models, ​BGP-15 treatment is associated with increased phosphorylation of the ​insulin-like growth factor 1 receptor (​IGF1R), which is depressed in atrial tissue samples from patients with AF. Cardiac-specific ​IGF1R transgenic overexpression in mice with HF and AF recapitulates the protection observed with ​BGP-15. We further demonstrate that ​BGP-15 and ​IGF1R can provide protection independent of phosphoinositide 3-kinase-Akt and heat-shock protein 70; signalling mediators often defective in the aged and diseased heart. As ​BGP-15 is safe and well tolerated in humans, this study uncovers a potential therapeutic approach for HF and AF.

来源: Nature Communications 浏览次数:74


RSS订阅 - 填写您的邮件地址,订阅我们的精彩内容: - 网站地图
网站联系电话:020-87540820 备案号:粤ICP备11050685号-8 增值电信业务经营许可证:粤B2-20120479
©2011-2015 生物帮 All rights reserved.